Discussion of findings
The study provides health utility estimates for a large cohort of SCD and MCI patients. The longitudinal study shows a significant decline in EQ-5D utility over time in moderate and severe dementia and a graded decrease in VAS with advancing clinical stages. Additionally, amyloid-positive patients have a steeper decline in health utility than amyloid-negative patients irrespective of the clinical stage. Older age, female sex, higher BMI, presence of diabetes, cardiovascular history, institutionalisation, higher depression score, and functional impairment are associated with poor HR-QoL.
We compare our estimated health utility for individuals with SCD to findings from two population-based surveys that utilised self-reported EQ-5D measures to study HR-QoL in the general population with SCD. The first study, conducted in Germany with a sample size of 3708, reported a health utility estimate of 0.89 (SD = 0.14) [
32] while the second study, a nationwide cohort in Korea with a sample size of 37,364, reported an estimate of 0.83 (SD = 0.16) [
33]. The main difference between our study and the aforementioned studies lies in the study design and sample population. Our study utilised a clinic-based cohort, where patients with cognitive complaints presented to memory clinics, while the two population-based surveys included more heterogeneous populations recruited in the community. Therefore, our estimated health utility of 0.84 is likely more representative of SCD individuals within the AD continuum.
The observed health utility in MCI patients can be compared to two studies that utilised patient-reported EQ-5D measures and shared the same study setting with ours [
20,
34]. Heßmann et al. estimated a health utility of 0.72 (SD = 0.28) in 50 patients with a mean age of 76 years [
20], while Jönsson et al. found an estimate of 0.84 in 47 patients with a mean age of 74 years [
34]. The relatively lower health utility estimate in Heßmann et al.’s study might be explained by the older age and longer time (3.8 ± 4.4 years) spent in the disease stage. A systematic review indicates a wide variation of health utility estimates ranging from 0.72 to 0.89 in MCI patients depending on the study setting and population demographics [
17]. Therefore, our estimate of 0.81 in the MCI population seems consistent with previous studies.
The health utilities from biomarker-informed SCD and MCI populations can be compared to the Swedish BioFINDER study, which shares a similar study setting and patient demographics to our study [
18]. Our health utility estimates of 0.85 in amyloid-negative SCD and 0.86 in amyloid-positive SCD are comparable to the CU population in the Swedish BioFINDER study. However, the health utility estimates of 0.83 in amyloid-negative MCI and 0.84 in amyloid-positive MCI are higher than the corresponding estimates of 0.71 and 0.8 in the Swedish BioFINDER study. The differences between the two studies might be due to the differences in comorbidities and NPS shared by the two cohorts. Additionally, HR-QoL is a complex construct that can vary widely based on patient characteristics and other unmeasured factors, such as relationships with caregivers [
35]. Therefore, the observed variation in health utility estimates between the two populations seems to be reasonable.
Domain analysis in our study shows that anxiety/depression and pain/discomfort are the most affected domains in individuals with SCD and MCI. The findings are consistent with the results from the BioFINDER study where more than 50% of participants reported having moderate to severe problems in the two domains [
18]. Pain is a common non-specific symptom in the elderly population and is more commonly reported in SCD and MCI than in dementia [
36]. The study also found that mobility, self-care, and usual activity domains were relatively unaffected, which is within expectation because patients with SCD and MCI can perform activities of daily living independently. These domains are typically affected in later disease stages when functional impairment becomes prominent. These findings provide valuable insights for understanding the impact of cognitive decline on HR-QoL domains in SCD and MCI stages.
The study reveals a faster decline of health utility in individuals with moderate and severe dementia over time and a constant decline in VAS with advancing clinical stages. The findings are consistent with previous research indicating that HR-QoL is lower with cognitive decline in individuals with SCD, MCI, and dementia [
18,
20,
21]. However, the health utility decline in moderate and severe dementia was not significant anymore after adjusting for IADL (Table
4). In AD, cognitive decline precedes and predicts functional impairment [
37] which manifests as limitations in complex IADLs such as medication intake, telephone use, and financial organisation in the early stage of the disease [
38]. As the disease progresses, functional limitation is prominent in basic functions such as eating, dressing, and toileting leading to care dependency and poor HR-QoL [
38]. A study by Janssen et al. on people at risk of dementia shows that the association between cognition and HR-QoL is mediated by IADL [
39]. The steeper decline of health utility in moderate and severe dementia might be explained by the mediation effect of prominent functional impairment in these stages.
Similar to IADL, Janssen et al. have shown that depression is a mediator between the association of cognition and HR-QoL [
39]. Our study shows a negative association between depressive symptoms and HR-QoL, which concurs with findings from previous research in SCD and MCI populations [
18,
33]. Depression is a core NPS in AD and related dementias [
40]. It typically manifests early in cognitive decline and is linked to disease progression and functional impairment [
41]. Moreover, depression usually coexists with SCD, and both are early manifestations of AD and related dementia [
42]. The study highlights the importance of considering depression in studying HR-QoL in AD.
The results of our study confirm previous findings that older age, female sex [
32,
43,
44], institutionalisation, and functional dependence [
20,
21] are predictors for lower HR-QoL. The higher depression scores in our study might explain the lower HR-QoL in females (Table S
3 in additional file). This finding aligns with previous research indicating that females tend to report higher SCD and depressive symptoms [
1] and patient-rated depressive symptoms are an independent predictor of HR-QoL [
3]. We did not see any association between education and HR-QoL. The association between education and HR-QoL are conflicting in previous studies with a cross-sectional study showing a positive association [
32] while a longitudinal study showed no association in SCD populations [
43]. The association in our study might have been attenuated by the influence of other key factors of dementia like depression and IADL. We also found that modifiable risk factors for dementia development such as diabetes, cardiovascular diseases, and obesity were associated with poor HR-QoL in SCD and MCI patients. This suggests that multidomain health interventions targeting these modifiable risk factors to prevent dementia development [
45] may also help to maintain HR-QoL in individuals with SCD.
Furthermore, our study reveals a faster decline of HR-QoL in amyloid-positive than amyloid-negative patients. This could be explained by a faster decline in cognitive and functional ability in individuals with amyloid-positive findings. A recent longitudinal study using data from Amsterdam Dementia Cohort also showed a faster decline of HR-QoL in amyloid-positive SCD and MCI patients [
19], although a direct comparison between the two studies is challenging due to differences in the analysis approach. Further longitudinal studies investigating the relationship between amyloid status and HR-QoL are needed.
Strengths and limitations
The study population comes from the nationwide memory clinic cohort with specific diagnostic criteria for SCD and MCI populations. The utility estimated from this cohort is representative of the SCD and MCI population and can be applied directly to the health economic models evaluating interventions in these populations. Moreover, we present utility for both general estimates and biomarker-confirmed SCD and MCI patients, allowing researchers to choose from the different estimates based on the target populations. In addition, the study’s longitudinal design provides insight into the HR-QoL trajectory along the disease continuum and allows us to establish the relationship between predictors for HR-QoL in the early stage of AD.
The limitation of this study is the use of patient-rated EQ-5D. Although patients with SCD and MCI can be considered competent to rate their own HR-QoL, studies suggested that patient-rated HR-QoL is consistently higher than the proxy-rated version in the dementia stage [
17]. Using patient-rated EQ-5D to assess the HR-QoL as the disease progresses might underestimate the magnitude of HR-QoL decline over time. Another limitation relates to the optional nature of biomarker testing within our cohort. Notably, individuals who underwent biomarker testing in our study displayed a healthier profile compared to those who did not receive this testing (Table S
4 of additional file). Consequently, there is a possibility that HR-QoL estimates for this subgroup may overstate the HR-QoL within the broader population. However, it is worth noting that we also provided HR-QoL estimates for the entire cohort, aiming to ensure that our findings are representative of the SCD and MCI populations, whether or not they underwent biomarker testing. Additionally, longitudinal studies involving dementia patients often encounter issues associated with selective dropout where patients with severe disease are more likely to be lost to follow-up which might further lead to an underestimation of HR-QoL decline in the severe disease stage.